title: Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.
abstract: OBJECTIVE
  To report the changes and trends in intraocular pressures (IOP) following intravitreal injection of Pegaptanib (Macugen) for the treatment of exudative age-related macular degeneration.
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  Review of 79 patients who underwent 122 consecutive Pegaptanib injections. Analysis of the short-term effect of Pegaptanib injections on IOP was performed.
  
  
  RESULTS
  Baseline mean IOP was 15.73 +/- 3.41 mm Hg (mean +/- standard deviation) with a range of 9 to 27 mm Hg. Postinjection mean IOP was 24.47 +/- 6.29 mm Hg with a range of 8 to 36 mm Hg. Mean IOP change from baseline to roughly 30 minutes after Pegaptanib injection was 8.74 +/- 7.23 mm Hg. At the 5- to 7-day follow-up visit, IOP had normalized.
  
  
  CONCLUSIONS
  Pegaptanib injection in this limited series seems to be safe from an IOP standpoint in the short-term. IOP monitoring postinjection may not be necessary.
authors.affiliation: Department of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois, USA.
authors.forename: Seenu M
authors.initials: SM
authors.lastname: Hariprasad
authors.forename: Gaurav K
authors.initials: GK
authors.lastname: Shah
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Blinder
mesh_terms: D052157:Aptamers, Nucleotide / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008268:Macular Degeneration / Q000188:drug therapy*; D012189:Retrospective Studies; D014065:Tonometry, Ocular; D014822:Vitreous Body
chemical_list: D052157:Aptamers, Nucleotide; C495058:pegaptanib